ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.313C>T (p.Pro105Ser) (rs13306510)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
LDLR-LOVD, British Heart Foundation RCV000237815 SCV000294602 likely benign Familial hypercholesterolemia 1 2016-03-25 criteria provided, single submitter literature only
Color Health, Inc RCV000775033 SCV000909130 uncertain significance Familial hypercholesterolemia 2020-10-19 criteria provided, single submitter clinical testing This missense variant (also known as p.Pro84Ser in the mature protein) replaces proline with serine at codon 105 of the LDLR protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. The variant has been reported in individuals affected with moderate familial hypercholesterolemia in the literature (PMID 9137885 15998910 18607183). This variant has been identified in 23/282822 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000781506 SCV000919588 uncertain significance not specified 2018-11-12 criteria provided, single submitter clinical testing Variant summary: LDLR c.313C>T (p.Pro105Ser) results in a non-conservative amino acid change located in the Low-density lipoprotein (LDL) receptor class A repeat region of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 9.4e-05 in 277426 control chromosomes (gnomAD and publication). This frequency is not significantly higher than expected for a pathogenic variant in LDLR causing Familial Hypercholesterolemia (9.4e-05 vs 0.0013), allowing no conclusion about variant significance. c.313C>T has been reported in the literature in individuals affected with Familial Hypercholesterolemia including a family that suggests lack of cosegregation with disease (Vuorio_1997). These report(s) do not provide unequivocal conclusions about association of the variant with Familial Hypercholesterolemia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. A ClinVar submission from a clinical diagnostic laboratory (evaluation after 2014) cite the variant as likely benign. Based on the evidence outlined above, the variant was classified as VUS-possibly benign.
Invitae RCV000775033 SCV001418365 uncertain significance Familial hypercholesterolemia 2019-01-16 criteria provided, single submitter clinical testing This sequence change replaces proline with serine at codon 105 of the LDLR protein (p.Pro105Ser). The proline residue is weakly conserved and there is a moderate physicochemical difference between proline and serine. This variant is present in population databases (rs13306510, ExAC 0.08%). This variant has been observed in several individuals with elevated cholesterol and reported to segregate with hypercholesterolemia in a family (PMID: 9137885). This variant is also described as Pro84Ser (P84S) in the literature. ClinVar contains an entry for this variant (Variation ID: 251132). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The serine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Natera, Inc. RCV000775033 SCV001456138 uncertain significance Familial hypercholesterolemia 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.